

online from January 2009



in vivo

International Journal of Experimental and Clinical
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GOKHALE, J.-C. RWIGEMA, M. EPPERLY, J. GLOWACKI, H. WANG, P. WIPF., J. GOFF, T. DIXON, K. PATRENE, J.S. GREENBERGER (*Pittsburgh, PA; Boston, MA, USA*)

A Non-traumatic *Staphylococcus aureus* Osteomyelitis Model in Pigs. H.E. JENSEN, O.L.NIELSEN, J.S. AGERHOLM, T. IBURG, L.K. JOHANSEN, E. JOHANNESSEN, M. MØLLER, L. JAHN, L. MUNK, B. AALBZ K, P.S. LEIFSSON (*Frederiksberg C, Denmark*)

Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDKUHL, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (*Bethesda, MD; Notre Dame, IN, USA*)

Uterus Cryopreservation in the Sheep: One Step Closer to Uterus Transplantation. R. DITTRICH, T. MALTARIS, A. MUELLER, O. STRAHL, I. HOFFMANN, M.W. BECKMANN, P.G. OPPELT (*Erlangen, Germany*)

Modulation of Aged Murine T Lymphocytes *In Vivo* by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (*Los Angeles, CA, USA*)

Twice Weekly Intravenous Treatment of Pancreatic Cancer with Atrial Natriuretic Peptide and Vessel Dilator. A. LENZ, Y. SUN, E.J. EICHELBAUM, W.P. SKELTON, IV, G. PI, D.L. VESELY (*Tampa, FL, USA*)

Successful Anatomic Repair of Fetoscopic Access Sites in the Mid-gestational Rabbit Model using Amnion Cells Engineering. N.A. PAPADOPULOS, D.I. KYRIAKIDIS, U. SCHILLINGER, A. TOTIS, J. HENKE, L. KOVACS, R.E. HORCH, K.T.M. SCHNEIDER, H.-G. MACHENS, E. BIEMER (*Munich; Erlangen, Germany*)

Effects of Fetal Exposure to 4-*n*-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (*Kagoshima, Japan*)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma *In Vivo*. X. CHEN, R.J. SWANSON, K.H. SCHOENBACH, S. ZHENG (*Zhejiang, China; Norfolk, VA, USA*)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNNA, G. ROSSONI (*Milan, Italy*)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDAL, K.-M. MYHR, H.I. YLAND (*Bergen, Norway*)

Development of fMRI Tests for Children with Central Auditory Processing Disorders. S. BARTEL-FRIEDRICH, Y. BROECKER, M. KNOERGEN, S. KOESLING (*Halle/Saale, Germany*)

Chronic Hind Limb Ischemia Reduces Myocardial Ischemia-reperfusion Injury in the Rabbit Heart by Promoting Coronary Angiogenesis/Arteriogenesis. V.C. VARNAVAS, K.I. PARASKEVAS, E.K. ILIODROMITIS, A. ZOGA, I. GLAVA, L. KAKLAMANIS, J. SPARTINOS, T. LYRAS, D.T. KREMASTINOS, D.P. MIKHAILIDIS, Z.S. KYRIAKIDES (*Athens, Greece; London, UK*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009) - VOL.7 (2010)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (*Penzburg, Germany; Vienna, Austria*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (*Grenoble, France*)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (*Cardiff, UK; Beijing, China*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (*Berlin, Germany*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, C.L. AUKIM-HASTIE (*Portsmouth; Southampton, UK; Riyadh, Saudi Arabia; Boston, MA, USA*)

Identification of Serpin (α -1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (*Moscow, Russia; Mainz, Germany*)

DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India*)

The Size of Colon Polyps Revisited: Intra and Inter-observer Variations. C.A. RUBIO, J.G. JÓNASSON, G. NESI, J. MAZUR, E. ÓLAFSDÓTTIR (<i>Stockholm, Sweden; Reykjavik, Iceland; Florence, Italy; Warsaw, Poland</i>)	2419
Number of Hysteroscopies and the Time Interval between Hysteroscopy and Surgery: Influence on Peritoneal Cytology in Patients with Endometrial Cancer. I. JUHASZ-BÖSS, T. FEHM, A. NAUTH, S. BECKER, R. ROTHMUND, K. GARDANIS, B. KRÄMER, D. WALLWIENER, E. SOLOMAYER (<i>Tübingen; Homburg/Saar, Germany</i>).....	2425
Frequent Expression of Thymidine Phosphorylase in Epstein-Barr Virus-associated Gastric Carcinoma of Diffuse Type. C. KORIYAMA, S. AKIBA, S. SHIMAOKA, T. ITOH, S.-I. AKIYAMA, Y. EIZURU (<i>Kagoshima, Japan</i>).....	2431
HER-2/AKT Expression in Upper Urinary Tract Urothelial Carcinoma: Prognostic Implications. L. IZQUIERDO, D. TRUAN, L. MENGUAL, C. MALLOFRÉ, A. ALCARAZ (<i>Barcelona; Santander, Spain</i>)	2439
Increased ERCC1 Protein Expression Is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer. F. LIN, K. LIN, X. XIE, C. ZHOU (<i>Zhejiang, PR China</i>)	2447
Prognostic Impact of CD133 Expression in Gastric Carcinoma. S. ISHIGAMI, S. UENO, T. ARIGAMI, Y. UCHIKADO, T. SETOYAMA, H. ARIMA, Y. KITA, H. KURAHARA, H. OKUMURA, M. MATSUMOTO, Y. KIJIMA, S. NATSUGOE (<i>Kagoshima, Japan</i>)	2453
Lack of Prognostic Value of Topoisomerase II Alpha in Patients with Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, H. ZHANG, C.-C. HUANG, R.-P. TANG (<i>Taoyuan, Taiwan, ROC; Xiamen, PR China</i>)	2459
Circulating <i>HER2</i> DNA after Trastuzumab Treatment Predicts Survival and Response in Breast Cancer. B.S. SORENSEN, L.S. MORTENSEN, J. ANDERSEN, E. NEXO (<i>Aarhus, Denmark</i>)	2463
Medical History and Lifestyle Factors Contributing to Epstein-Barr Virus-Associated Gastric Carcinoma and Conventional Gastric Carcinoma in Korea. R.H. KIM, M.S. CHANG, H.J. KIM, K.S. SONG, Y.S. KIM, B.Y. CHOI, W.H. KIM (<i>Seoul; Daejeon, South Korea</i>)	2469
Meeting Report: City of Temples Discusses Signaling Templates in Cancer Cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy Bhubaneswar, Orissa, India, December 18th through 21st, 2009. V. GANDHI, K. MEHTA, S. PATHAK, B. RAVINDRAN, S. MISHRA, B.B. AGGARWAL (<i>Houston, TX, USA; Orissa, India</i>)	2477
Errata	2481

* Reviews (pages 1977, 2073, 2161)

A Phase IA, Open-label, Dose-escalating Study of PTK787/ZK 222584 Administered Orally on a Continuous Dosing Schedule in Patients with Advanced Cancer. J. DREVS, M. MEDINGER, K. MROSS, S. FUXIUS, J. HENNIG, M. BUECHERT, A. THOMAS, C. UNGER, B.-L. CHEN, D. LEBWOHL, D. LAURENT (<i>Freiburg; Heidelberg; Berlin, Germany; Leicester, UK; East Hanover, NJ, USA</i>).....	2335
Postoperative Concurrent Daily Low-dose Cisplatin-based Chemoradiation Improves the Prognosis of Patients with Pathologic T2b or N1 Cervical Cancer. A. MITSUHASHI, T. UNO, H. USUI, S. TATE, K. HIRASHIKI, K. KATO, H. KIYOHARA, S. KATO, H. ITO, M. SHOZU (<i>Chiba, Japan</i>)	2341
An Indication for Correlation between the Serum ADA Level and Gastric Cancer Risk. G. RI, S. OHNO, M. FURUTANI, Y. FURUTANI, T. TSUKAHARA, N. HAGITA, H. HARUYAMA, S. NAKAMURA, T. YAMAMOTO, R. MATSUOKA (<i>Tokyo; Saitama, Japan</i>)	2347
A Case of Spontaneous Regression of Advanced Colon Cancer. H. SHIMIZU, M. KOCHI, T. KAIGA, Y. MIHARA, M. FUJII, T. TAKAYAMA (<i>Tokyo, Japan</i>)	2351
Pharmacokinetics of Irinotecan in Combination with Biweekly Cetuximab in Patients with Advanced Colorectal Cancer. M. CZEJKA, B. GRUENBERGER, A. KISS, A. FARKOUH, J. SCHUELLER (<i>Vienna, Austria</i>)	2355
Clinical Significance of Vascular Endothelial Growth Factors C and D and Chemokine Receptor CCR7 in Gastric Cancer. K. DEGUCHI, D. ICHIKAWA, K. SOGA, K. WATANABE, T. KOSUGA, H. TAKESHITA, H. KONISHI, R. MORIMURA, M. TSUJIURA, S. KOMATSU, A. SHIOZAKI, K. OKAMOTO, H. FUJIWARA, E. OTSUJI (<i>Kyoto, Japan</i>)	2361
Indication for Hepatic Resection in the Treatment of Liver Metastasis from Gastric Cancer. H. MAKINO, C. KUNISAKI, Y. IZUMISAWA, M. TOKUHISA, T. OSHIMA, Y. NAGANO, S. FUJII, J. KIMURA, R. TAKAGAWA, T. KOSAKA, H.A. ONO, H. AKIYAMA, K. TANAKA, I. ENDO (<i>Yokohama, Japan</i>).....	2367
Detection of Circulating Tumour Cells in Breast Cancer Patients Using Human Mammaglobin RT-PCR: Association with Clinical Prognostic Factors. P. FERRO, M.C. FRANCESCHINI, B. BACIGALUPO, P. DESSANTI, E. FALCO, V. FONTANA, D. GIANQUINTO, M.P. PISTILLO, F. FEDELI, S. RONCELLA (<i>La Spezia; Genova, Italy</i>)	2377
Post-transplant Lymphoproliferative Disorders in Liver Transplanted Patients: A Single-centre Experience. D. MARINO, P. BURRA, P. BOCCAGNI, F. CALABRESE, F. CANOVA, C. TRENTIN, C. BOSO, C. SOLDÀ, P. ANGELI, S.M.L. AVERSA (<i>Padova, Italy</i>)	2383
Association of Hypoxia-inducible Factor 1-alpha Gene Polymorphisms and Colorectal Cancer Prognosis. J. SZKANDERA, G. KNECHTEL, M. STOTZ, G. HOFMANN, U. LANGSENLEHNER, P. KRIPPL, T. LANGSENLEHNER, D. DEHCHAMANI, H. SAMONIGG, W. RENNER, A. GERGER (<i>Graz; Fuerstenfeld, Austria</i>)	2393
Evaluation of Women with Breast Disease Using Body Image Drawing Analysis. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>).....	2399
Prognostic Relevance of <i>KIT</i> and <i>PDGFRA</i> Mutations in Gastrointestinal Stromal Tumors. E. BRAGGIO, D. DE ALMEIDA BRAGGIO, I.Á. SMALL, L.F. LOPES, M. VALADÃO, M.E. GOUVEIA, A. DOS SANTOS MOREIRA, E. LINHARES, S. ROMANO, C.E. BACCHI, I.Z. RENAULT, D.P. GUIMARÃES, C.G. FERREIRA (<i>São Paulo; Rio de Janeiro, Brazil</i>)	2407
Impact of Post-transplant Imatinib Administration on Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. S. NISHIWAKI, K. MIYAMURA, C. KATO, S. TERAOKA, K. OHASHI, H. SAKAMAKI, S. NAKAO, H. HARIGAE, Y. KODERA (<i>Nagoya; Sendai; Tokyo; Kanazawa, Japan</i>)	2415

Clinical Studies

A Clear Correlation between WT1-specific Th Response and Clinical Response in WT1 CTL Epitope Vaccination. F. FUJIKI, Y. OKA, M. KAWAKATSU, A. TSUBOI, Y. TANAKA-HARADA, N. HOSEN, S. NISHIDA, T. SHIRAKATA, H. NAKAJIMA, N. TATSUMI, N. HASHIMOTO, T. TAGUCHI, S. UEDA, N. NONOMURA, Y. TAKEDA, T. ITO, A. MYOUI, S. IZUMOTO, M. MARUNO, T. YOSHIMINE, S. NOGUCHI, A. OKUYAMA, I. KAWASE, Y. OJI, H. SUGIYAMA (<i>Osaka; Nishinomiya, Japan</i>)	2247
Phase I Study of Oral Vinorelbine and Capecitabine in Patients with Metastatic Breast Cancer. A. ANTON, A. LLUCH, A. CASADO, M. PROVENCIO, M. MUÑOZ, J. LAO, B. BERMEJO, A.B. PAULES, J. GAYO, M. MARTIN (<i>Zaragoza; Valencia; Madrid; Barcelona, Spain</i>)	2255
Effects of α -Difluoromethylornithine on Markers of Proliferation, Invasion, and Apoptosis in Breast Cancer. E. IZBICKA, R.T. STREPPER, I-T. YEH, O. PRESSLEY, M. GRANT, J. V.R. ANDREWS, J. KUHN, J. O'SHAUGHNESSY (<i>San Antonio; Dallas, TX, USA</i>)	2263
Connexin43, E-Cadherin, β -Catenin and ZO-1 Expression, and Aberrant Methylation of the Connexin43 Gene in NSCLC. Y. JINN, N. INASE (<i>Kanagawa; Tokyo, Japan</i>)	2271
Aberrant Expression of Vimentin Correlates with Dedifferentiation and Poor Prognosis in Patients with Intrahepatic Cholangiocarcinoma. P.V. KORITA, T. WAKAI, Y. AJIOKA, M. INOUE, M. TAKAMURA, Y. SHIRAI, K. HATAKEYAMA (<i>Niigata, Japan</i>)	2279
Surgical Excision for B3 Breast Lesions Diagnosed by Vacuum-assisted Core Biopsy. S. REEFY, H. OSMAN, C. CHAO, N. PERRY, K. MOKBEL (<i>London; Tooting, UK</i>)	2287
Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharynx. K. ALKOTYFAN, S. WIEGAND, H.-H. MÜLLER, J.P. WINDFUHR, J.A. WERNER, A.M. SESTERHENN (<i>Marburg; Moenchengladbach, Germany</i>)	2291
The Impact of the Extent of Lymph-node Dissection on Biochemical Relapse after Radical Prostatectomy in Node-negative Patients. R. SCHIAVINA, A. BERTACCINI, A. FRANCESCHELLI, F. MANFERRARI, V. VAGNONI, M. BORGHESI, A.M. MORSELLI-LABATE, G. MARTORANA (<i>Bologna, Italy</i>)	2297
Vincristine in High-grade Glioma. B. AYDIN, M. PATIL, N. BEKELE, J.E.A. WOLFF (<i>Ankara, Turkey; Houston, TX, USA</i>)	2303
Vulvar Cancer: Prognostic Factors. M.O. NICOLETTO, A. PARENTI, P. DEL BIANCO, G. LOMBARDI, L. PEDRINI, S. PIZZI, P. CARLI, M. DELLA PALMA, D. PASTORELLI, L. CORTI, L. BECAGLI (<i>Padova, Italy</i>)	2311
Short-term Outcome of Cervical Intraepithelial Neoplasia Grade 2: Considerations for Management Strategies and Reproducibility of Diagnosis. A.C. GUEDES, L.C. ZEFERINO, K.J. SYRJÄNEN, S.M.F. BRENNAN (<i>São Paulo, Brazil; Turku, Finland</i>)	2319
Polymorphisms of Thymidylate Synthase Gene 5'- and 3'-Untranslated Region and Risk of Gastric Cancer in Koreans. D.J. YIM, O.J. KIM, H.J. AN, H. KANG, D.H. AHN, S.G. HWANG, D. OH, N.K. KIM (<i>Seongnam, South Korea</i>)	2325
Relationship between Preoperative Serum Markers CA 15-3 and CEA and Relapse of the Disease in Elderly (>65 years) Women with Breast Cancer. F. LUMACHI, S.M.M. BASSO, M. BONAMINI, B. MARZANO, E. MILAN, B.U. WACLAW, G.B. CHIARA (<i>Padova; Pordenone, Italy</i>)	2331

Inhibition of Heme Oxygenase-1 Enhances the Cytotoxic Effect of Gemcitabine in Urothelial Cancer Cells. M. MIYAKE, K. FUJIMOTO, S. ANAI, S. OHNISHI, Y. NAKAI, T. INOUE, Y. MATSUMURA, A. TOMIOKA, T. IKEDA, E. OKAJIMA, N. TANAKA, Y. HIRAO (<i>Nara, Japan</i>)	2145
SDF1/CXCL12 Is Involved in Recruitment of Stem-like Progenitor Cells to Orthotopic Murine Malignant Mesothelioma Spheroids. B.W. LAU, A.B. KANE (<i>Providence, RI, USA</i>)	2153
* Review: Liver Regeneration and its Impact on Post-hepatectomy Metastatic Tumour Recurrence. K.A. PASCHOS, N.C. BIRD (<i>Sheffield, UK</i>)	2161
Effect of Dietary Astaxanthin at Different Stages of Mammary Tumor Initiation in BALB/c Mice. R. NAKAO, O.L. NELSON, J.S. PARK, B.D. MATHISON, P.A. THOMPSON, B.P. CHEW (<i>Pullman, WA, USA</i>)	2171
Biodistribution of Two Octreotate Analogs Radiolabeled with Indium and Yttrium in Rats. A. LAZNICKOVA, M. LAZNICEK, F. TREJTNAR, H.R. MAECKE, K.P. EISENWIENER, J.C. REUBI (<i>Hradec Kralove, Czech Republic; Basel; Berne, Switzerland</i>)	2177
Nuclear Morphometry in Prognostication of Breast Cancer in Saudi Arabian Patients: Comparison with European and African Breast Cancer. A. BUHMEIDA, J. AL-MAGHRABI, A. MERDAD, F. AL-THUBAITY, A. CHAUDHARY, M. GARI, A. ABUZENADAH, Y. COLLAN, K. SYRJÄNEN, M. AL-QAHTANI (<i>Jeddah, Saudi Arabia; Turku, Finland</i>)	2185
Induction of Apoptosis by Gene Transfer of Human <i>TRAIL</i> Mediated by Arginine-rich Intracellular Delivery Peptides. J.-F. LI, Y. HUANG, R.-L. CHEN, H.-J. LEE (<i>Hualien; Tainan, Taiwan, ROC</i>)	2193
Insulin-like Growth Factors II exon 9 and E-cadherin-Pml I but not Myeloperoxidase Promoter-463, Urokinase- <i>ApaL</i> I nor Xeroderma Pigmentosum Polymorphisms Are Associated with Higher Susceptibility to Leiomyoma. Y.-Y. HSIEH, C.-C. CHANG, Y.-K. WANG, K.-H. HSU, C.-P. CHEN, C.-M. HSU, F.-J. TSAI (<i>Taichung; Hsin-Chu; Taipei, Taiwan, ROC</i>)	2203
CXCR4, A Potential Predictive Marker for Docetaxel Sensitivity in Gastric Cancer. L. XIE, J. WEI, X. QIAN, G. CHEN, L. YU, Y. DING, B. LIU (<i>Nanjing, PR China</i>)	2209
Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts. M. ZHAO, C. LIANG, A. LI, J. CHANG, H. WANG, R. YAN, J. ZHANG, J. TAI (<i>Beijing; Tianjin, PR China</i>)	2217
Promoter Polymorphisms and Methylation of E-Cadherin (<i>CDH1</i>) and <i>KIT</i> in Gastric Cancer Patients from Northern Brazil. B.D.N. BORGES, E. DA SILVA SANTOS, C.E.M. CARVALHO BASTOS, L.C. PINTO, N.P. ANSELMO, J.A. QUARESMA, D.Q. CALCAGNO, R.M.R. BURBANO, M.L. HARADA (<i>Belém, Pará, Brazil</i>)	2225
Impact of the Menstrual Cycle on Circulating Cell-free DNA. M. PÖLCHER, J. ELLINGER, S. WILLEMS, O. EL-MAARRI, T. HÖLLER, C. AMANN, M. WOLFGARTEN, C. RUDLOWSKI, W. KUHN, M. BRAUN (<i>Bonn, Germany</i>)	2235
Sonodynamically Induced Cell Damage and Membrane Lipid Peroxidation by Novel Porphyrin Derivative, DCPH-P-Na(I). N. YUMITA, Y. IWASE, K. NISHI, T. IKEDA, S.-I. UMEMURA, I. SAKATA, Y. MOMOSE (<i>Kanagawa; Sendai; Okayama; Chiba, Japan</i>)	2241

AKT and p21 ^{WAF1/CIP1} as Potential Genistein Targets in <i>BRCAl</i> -mutant Human Breast Cancer Cell Lines. M. PRIVAT, C. AUBEL, S. ARNOULD, Y. COMMUNAL, M. FERRARA, Y.-J. BIGNON (<i>Clermont-Ferrand, France</i>)	2049
The Influence of Electroporation on Cytotoxicity of Anticancer Ruthenium(III) Complex KP1339 <i>In Vitro</i> and <i>In Vivo</i> . R. HUDEJ, I. TUREL, M. KANDUSER, J. SCANCAR, S. KRANJC, G. SERSA, D. MIKLAVCIC, M.A. JAKUPEC, B.K. KEPPLER, M. CEMAZAR (<i>Ljubljana, Slovenia; Vienna, Austria</i>).....	2055
Cisplatin Augments FAS-mediated Apoptosis through Lipid Rafts. C.-R. HUANG, Z.-X. JIN, L. DONG, X.-P. TONG, S. YUE, T. KAWANAMI, T. SAWAKI, T. SAKAI, M. MIKI, H. IWAO, A. NAKAJIMA, Y. MASAKI, Y. FUKUSHIMA, M. TANAKA, Y. FUJITA, H. NAKAJIMA, T. OKAZAKI, H. UMEHARA (<i>Ishikawa; Tottori, Japan; Wuhan, Hubei, PR China</i>)	2065
* Review: An Overview of Nanotechnology-based Functional Proteomics for Cancer and Cell Cycle Progression. C. NICOLINI, E. PECHKOVA (<i>Genoa, Rome, Italy</i>)	2073
Long-term Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Pulsed Dendritic Cells. M. KRAEMER, S. HAUSER, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>)	2081
Clioquinol Independently Targets NF- κ B and Lysosome Pathways in Human Cancer Cells. H. YU, J.R. LOU, W.-Q. DING (<i>Wuhan, PR China; Oklahoma City, OK, USA</i>)	2087
Proteomic Analysis for Nuclear Proteins Related to Tumour Malignant Progression: A Comparative Proteomic Study Between Malignant Progressive Cells and Regressive Cells. Y. KURAMITSU, E. HAYASHI, F. OKADA, T. TANAKA, X. ZHANG, Y. UEYAMA, K. NAKAMURA (<i>Ube; Yamagata, Japan</i>)	2093
Antisense Inhibition of Amphiregulin Expression Reduces EGFR Phosphorylation in Transformed Human Breast Epithelial Cells. L. MA, E. HUET, M. SEROVA, Y. BERTHOIS, F. CALVO, S. MOURAH, S. MENASHI (<i>Beijing, PR China; Créteil; Paris; Marseille, France</i>)	2101
Attenuation of MG132-induced HeLa Cell Death by <i>N</i> -Acetyl Cysteine <i>via</i> Reducing Reactive Oxygen Species and Preventing Glutathione Depletion. Y.H. HAN, Y.M. YANG, S.Z. KIM, W.H. PARK (<i>Jeonju, Republic of Korea</i>)	2107
Analysis of Apoptotic Effects Induced by Photodynamic Therapy in a Human Biliary Cancer Cell Line. T. NONAKA, A. NANASHIMA, M. NONAKA, M. UEHARA, H. ISOMOTO, I. ASAHINA, T. NAGAYASU (<i>Nagasaki, Japan</i>)	2113
Differential <i>Ex Vivo</i> Activity of Bortezomib in Newly Diagnosed Paediatric Acute Lymphoblastic and Myeloblastic Leukaemia. J. SZCZEPANEK, M. POGORZALA, B. KONATKOWSKA, E. JURASZEWSKA, W. BADOWSKA, I. OLEJNIK, M. KUZMICZ, E. STANCZAK, I. MALINOWSKA, J. STEFANIAK, G. SOBOL, T. SZCZEPANSKI, K. CZYZEWSKI, M. WYSOCKI, J. STYCZYNSKI (<i>Bydgoszcz; Poznan; Cracow; Olsztyn; Chorzow; Bialystok; Warsaw; Lublin; Katowice; Zabrze, Poland</i>)	2119
Curcumin Induces Apoptosis in Human Non-small Cell Lung Cancer NCI-H460 Cells through ER Stress and Caspase Cascade- and Mitochondria-dependent Pathways. S.-H. WU, L.-W. HANG, J.-S. YANG, H.-Y. CHEN, H.-Y. LIN, J.-H. CHIANG, C.-C. LU, J.-L. YANG, T.-Y. LAI, Y.-C. KO, J.-G. CHUNG (<i>Changhua; Taichung; Chiayi; Taiwan, ROC</i>)	2125
Phenethyl Isothiocyanate Inhibits Migration and Invasion of Human Gastric Cancer AGS Cells through Suppressing MAPK and NF- κ B Signal Pathways. M.-D. YANG, K.-C. LAI, T.-Y. LAI, S.-C. HSU, C.-L. KUO, C.-S. YU, M.-L. LIN, J.-S. YANG, H.-M. KUO, S.-H. WU, J.-G. CHUNG (<i>Taichung; Yunlin; Changhua, Taiwan, ROC</i>)	2135

Bortezomib Therapeutic Effect Is Associated with Expression and Mutation of <i>FGFR3</i> in Human Lymphoma Cells. W. ZHENG, M. GUAN, L. ZHU, Z. CAI, V. CHUNG, H. HUANG, Y. YEN (<i>Zhejiang, PR China; Duarte, CA, USA</i>)	1921
Efficacy of Recombinant Adeno-Associated Viral Vectors Serotypes 1, 2, and 5 for the Transduction of Pancreatic and Colon Carcinoma Cells. C. TESCHENDORF, B. EMONS, N. MUZYCZKA, U. GRAEVEN, W. SCHMIEGEL (<i>Bochum, Germany; Gainesville, FL, USA</i>)	1931
Function and Regulatory Mechanisms of the Candidate Tumor Suppressor Receptor Protein Tyrosine Phosphatase Gamma (PTPRG) in Breast Cancer Cells. S.T. SHU, Y. SUGIMOTO, S. LIU, H.-L. CHANG, W. YE, L.-S. WANG, Y.-W. HUANG, P. YAN, Y.C. LIN (<i>Columbus, OH, USA</i>)	1937
VEGF Targeting in Mesotheliomas Using an Interleukin-6 Signal Inhibitor Based on Adenovirus Gene Delivery. Y. ADACHI, N. YOSHIO-HOSHINO, C. AOKI, N. NISHIMOTO (<i>Ibaraki-City; Suita City, Osaka, Japan</i>)	1947
Guggulsterone Suppresses Bile Acid-induced and Constitutive Caudal-related Homeobox 2 Expression in Gut-derived Adenocarcinoma Cells. T. YAMADA, S. OSAWA, Y. HAMAYA, T. FURUTA, A. HISHIDA, M. KAJIMURA, M. IKUMA (<i>Hamamatsu, Japan</i>)	1953
<i>In Vitro</i> Interaction of High-LET Heavy-ion Irradiation and Chemotherapeutic Agents in Two Cell lines with Different Radiosensitivities and Different <i>p53</i> Status. T. TAKAHASHI, T. FUKAWA, R. HIRAYAMA, Y. YOSHIDA, A. MUSHA, Y. FURUSAWA, K. ANDO, T. NAKANO (<i>Gunma; Chiba, Japan</i>)	1961
<i>KRAS</i> and <i>BRAF</i> Mutation Analysis from Liquid-based Cytology Brushings of Colorectal Carcinoma in Comparison with Formalin-fixed, Paraffin-embedded Tissue. A. SPATHIS, J. GEORGOULAKIS, P. FOUKAS, M. KEFALA, K. LEVENTAKOS, A. MACHAIRAS, I. PANAYIOTIDES, P. KARAKITSOS (<i>Athens, Greece</i>)	1969
* Review: On the Origin and Growth of Gliomas. D. SCHIFFER, L. ANNOVAZZI, V. CALDERA, M. MELLAI (<i>Turin, Italy</i>)	1977
A Novel Gene Delivery System Targeting Tie2 for Cancer Gene Therapy. A. HU, X. WU, Z. LI, H. WANG, J. LI, M. YAO, X. CHEN, S. QU, Y. XU, J. GU (<i>Shanghai, PR China</i>)	1999
Identification of Stem-like Cells in Head and Neck Cancer Cell Lines. G. SUN, M. FUJII, A. SONODA, Y. TOKUMARU, T. MATSUNAGA, N. HABU (<i>Tokyo, Japan</i>)	2005
Therapeutic Effects of Hybrid Liposomes on Gastric Carcinoma Involve Apoptosis. H. ICHIHARA, Y. MATSUOKA, Y. MATSUMOTO, R. UEOKA (<i>Kumamoto, Japan</i>)	2011
COX-2 Expression and Effects of COX-2 Inhibition in Colorectal Carcinomas and their Liver Metastases. H.-U. KASPER, E. KONZE, H.P. DIENES, D.L. STIPPEL, P. SCHIRMACHER, M. KERN (<i>Münster/Wfl.; Köln; Heidelberg, Germany</i>)	2017
Antiproliferative Effects of Antiestrogens and Inhibitors of Growth Factor Receptor Signaling on Endometrial Cancer Cells. M. BLOCK, S. FISTER, G. EMONS, S. SEEBER, C. GRÜNDKER, A.R. GÜNTHERT (<i>Göttingen, Germany; Bern, Switzerland</i>)	2025
Protective Effects of the Immunopotentiator from <i>Pantoea agglomerans</i> 1 on Chemotherapeutic Agent-induced Macrophage Growth Inhibition. T. HEBISHIMA, Y. MATSUMOTO, G. WATANABE, G.-I. SOMA, C. KOHCHI, K. TAYA, Y. HAYASHI, Y. HIROTA (<i>Tokyo; Gifu; Tokushima; Kagawa, Japan</i>)	2033
Inhibition of Wnt Signaling Pathway Decreases Chemotherapy-resistant Side-population Colon Cancer Cells. N. CHIKAZAWA, H. TANAKA, T. TASAKA, M. NAKAMURA, M. TANAKA, H. ONISHI, M. KATANO (<i>Fukuoka, Japan</i>)	2041